<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649541</url>
  </required_header>
  <id_info>
    <org_study_id>MRX8-101</org_study_id>
    <nct_id>NCT04649541</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts</brief_title>
  <official_title>An Adaptive, Randomized, Double Blind, Placebo Controlled Three Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX-8 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicuRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MicuRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is designed to assess the safety and tolerability of single and multiple&#xD;
      intravenous (IV) doses of MRX-8, to assess the pharmacokinetics of MRX-8 and its primary&#xD;
      metabolite following single and multiple IV doses, and to measure the elimination of MRX-8&#xD;
      and its metabolite in urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, randomized, double-blind, placebo-controlled study consisting of 3&#xD;
      parts. Part 1 will evaluate single ascending doses (SAD) of study drug. Part 2 will evaluate&#xD;
      multiple ascending doses (MAD) of study drug administered for 7 days. Part 3 will evaluate&#xD;
      MAD of study drug administered for 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Symptoms reported by subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical laboratory assessment</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Complete blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Cmax of MRX-8 and its primary metabolite following single and multiple intravenous doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Tmax of MRX-8 and its primary metabolite following single and multiple intravenous doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>AUC of MRX-8 and its primary metabolite following single and multiple intravenous doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Pre-dose through 48 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Heart rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination of MRX-8 and its primary metabolite in urine</measure>
    <time_frame>At the end of infusion through 24 hours after the end of infusion on the final infusion of study drug</time_frame>
    <description>Quantity of measurable MRX-8 and its primary metabolite excreted in urine</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Single intravenous doses of MRX-8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single escalating doses of MRX-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single intravenous doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intravenous doses of placebo to match MRX-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple intravenous doses of MRX-8 for 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple ascending intravenous doses of MRX-8 every 12 hours for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple intravenous doses of placebo for 7 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple intravenous doses of placebo every 12 hours for 7 days to match MRX-8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple intravenous doses of MRX-8 for 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple ascending intravenous doses of MRX-8 every 12 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple intravenous doses of placebo for 14 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple intravenous doses of placebo every 12 hours for 14 days to match MRX-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX-8</intervention_name>
    <description>novel semi-synthetic polymyxin B analog.</description>
    <arm_group_label>Multiple intravenous doses of MRX-8 for 14 days</arm_group_label>
    <arm_group_label>Multiple intravenous doses of MRX-8 for 7 days</arm_group_label>
    <arm_group_label>Single intravenous doses of MRX-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5% dextrose in water</description>
    <arm_group_label>Multiple intravenous doses of placebo for 14 days</arm_group_label>
    <arm_group_label>Multiple intravenous doses of placebo for 7 days</arm_group_label>
    <arm_group_label>Single intravenous doses of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  In good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior participation in a study utilizing a polymyxin or aminoglycoside antibiotic or&#xD;
             other nephrotoxic drug within the 12 months prior to study drug administration on Day&#xD;
             1&#xD;
&#xD;
          -  Use of tobacco or nicotine products, in any form, within 30 days prior to study drug&#xD;
             administration on Day 1&#xD;
&#xD;
          -  Venous access considered inadequate for IV infusions, laboratory safety assessments,&#xD;
             or PK sample collection&#xD;
&#xD;
          -  Underlying hepatic, renal, metabolic, cardiovascular or immunologic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical coordinator</last_name>
    <phone>510-782-2022</phone>
    <email>info@micurx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

